JP2018527895A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527895A5
JP2018527895A5 JP2017568233A JP2017568233A JP2018527895A5 JP 2018527895 A5 JP2018527895 A5 JP 2018527895A5 JP 2017568233 A JP2017568233 A JP 2017568233A JP 2017568233 A JP2017568233 A JP 2017568233A JP 2018527895 A5 JP2018527895 A5 JP 2018527895A5
Authority
JP
Japan
Prior art keywords
seq
hybridoma cell
cell line
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040011 external-priority patent/WO2017004151A1/en
Publication of JP2018527895A publication Critical patent/JP2018527895A/ja
Publication of JP2018527895A5 publication Critical patent/JP2018527895A5/ja
Pending legal-status Critical Current

Links

JP2017568233A 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 Pending JP2018527895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186109P 2015-06-29 2015-06-29
US62/186,109 2015-06-29
PCT/US2016/040011 WO2017004151A1 (en) 2015-06-29 2016-06-29 Anti-apobec3 antibodies and methods of making and using

Publications (2)

Publication Number Publication Date
JP2018527895A JP2018527895A (ja) 2018-09-27
JP2018527895A5 true JP2018527895A5 (enExample) 2019-08-22

Family

ID=57609413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568233A Pending JP2018527895A (ja) 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法

Country Status (4)

Country Link
US (1) US10752699B2 (enExample)
EP (1) EP3313993A4 (enExample)
JP (1) JP2018527895A (enExample)
WO (1) WO2017004151A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752699B2 (en) 2015-06-29 2020-08-25 Regents Of The University Of Minnesota Anti-APOBEC3 antibodies and methods of making and using
EP3732196A4 (en) * 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
WO2020190609A1 (en) * 2019-03-15 2020-09-24 Mayo Foundation For Medical Education And Research Oncolytic viruses and methods for using oncolytic viruses
EP3994167A4 (en) * 2019-07-02 2023-11-01 Astute Medical, Inc. ANTIBODIES AND ASSAY FOR CCL14
US20220396618A1 (en) * 2019-10-31 2022-12-15 The Research Foundation For The State University Of Newyork Rage antibodies, fragments and uses thereof
US20240376199A1 (en) * 2021-09-13 2024-11-14 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
CN117802095B (zh) * 2024-03-01 2024-06-25 广东工业大学 一种检测核酸胞嘧啶脱氨酶apobec3b活性的化学发光试剂盒及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030174A1 (en) 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US20110111424A1 (en) * 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
JP4653103B2 (ja) 2003-06-10 2011-03-16 ザ ジェイ．ディヴィッド グラッドストン インスティテューツ レンチウイルス感染症を治療するための方法
US8133666B2 (en) 2004-11-02 2012-03-13 The J. David Gladstone Institutes Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
US20070293525A1 (en) 2006-06-15 2007-12-20 Djung Jane F 2-anilino-4-aminoalkyleneaminopyrimidines
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
US9084762B2 (en) * 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
US20120252026A1 (en) 2011-04-01 2012-10-04 Harris Reuben S Cancer biomarker, diagnostic methods, and assay reagents
US20160008382A1 (en) 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2812016A2 (en) 2012-02-12 2014-12-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cellular apobec3 proteins and modulators thereof for regulating dna repair processes and treating proliferative disease
CA2882292C (en) 2012-08-13 2023-10-17 The Rockefeller University Treatment and diagnosis of melanoma
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
WO2014200898A2 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
US20160208249A1 (en) 2013-09-03 2016-07-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and Methods for Inducing Senescence in Cancer Cells
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
WO2016009017A1 (en) 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
GB201420859D0 (en) 2014-11-24 2015-01-07 Cancer Res Inst Royal Tumour analysis
US20200046671A1 (en) 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
US10752699B2 (en) 2015-06-29 2020-08-25 Regents Of The University Of Minnesota Anti-APOBEC3 antibodies and methods of making and using
US20180185302A1 (en) 2015-06-30 2018-07-05 Regents Of The University Of Minnesota Methods for downregulating apobec3b
US20190085405A1 (en) 2016-03-23 2019-03-21 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes

Similar Documents

Publication Publication Date Title
JP2018527895A5 (enExample)
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2017518366A5 (enExample)
JP2018042573A5 (enExample)
JP2017524725A5 (enExample)
JP2016026303A5 (enExample)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
JP2013506428A5 (enExample)
HRP20160461T1 (hr) Solubilna humana st-2 antitijela i eseji
Akter et al. Broad-spectrum noncompetitive immunocomplex immunoassay for cyanobacterial peptide hepatotoxins (microcystins and nodularins)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2016505634A5 (enExample)
JP2016516400A5 (enExample)
RU2008139098A (ru) Способы диагностики рака поджелудочной железы с применением белка reg4
JP2010539161A5 (enExample)
JP2010526880A5 (enExample)
JP2020516603A5 (enExample)
JP2016500659A5 (enExample)
RU2013142334A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а
JP7557023B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
RU2018103933A (ru) Моноклональные антитела, с ориентировкой на антиген Р респираторно-синцитиального вируса человека, получаемые и секретируемые из клеточных гибридом, используемые для обнаружения и диагностики инфекции, вызываемой респираторно-синцитиальным вирусом
JP2020189843A5 (enExample)
CN107921123A (zh) 骆驼源单域hcv抗体以及使用方法
RU2019110953A (ru) Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение
JP7455947B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具